Skip to content
Research/Peptides/Adipotide (FTPP)

Adipotide (FTPP)

compound

preclinical evidencePublic

Adipotide is a peptide designed for treating obesity by targeting white adipose tissue through a dual-domain mechanism that induces endothelial cell apoptosis. Preclinical studies indicate its effectiveness in weight reduction and metabolic improvement, although dose-dependent nephrotoxicity raises safety concerns. Formulation strategies are being explored to enhance its therapeutic potential while minimizing off-target effects.

Category: PeptidesUpdated 7/14/2026

Intelligence Profile

Overview

Adipotide (also known as FTPP) is an experimental peptide compound that has been investigated as a potential treatment for obesity and metabolic disorders. The compound is designed as a targeted therapy that aims to selectively destroy fat tissue by disrupting the blood supply to adipose (fat) cells, theoretically leading to fat loss and improved metabolic health.

The development of adipotide was based on the concept of targeting the vasculature that supplies fat tissue, with the goal of creating a pharmacological approach to weight loss that could be more targeted than traditional methods. The compound contains sequences that are intended to bind specifically to blood vessels in fat tissue, followed by a toxic payload designed to destroy those vessels and subsequently cause fat cell death.

However, it's important to note that comprehensive evidence for adipotide's safety and effectiveness in humans is extremely limited. No clinical trials or peer-reviewed studies were found in the current medical literature, which means there is insufficient data to evaluate its potential benefits, risks, or role in longevity and health optimization strategies. Without robust clinical evidence, the compound remains highly experimental, and its therapeutic potential cannot be properly assessed. Anyone considering this or similar experimental compounds should consult with qualified healthcare providers, as the safety profile and long-term effects remain unknown.

Biohacker actions
Check interactionsView protocols

Deep dive

Intelligence Profile

AI-EnrichedUpdated Jul 14, 2026

The Science

Mechanism of Action

Evidence Status: No peer-reviewed research available

No published studies, clinical trials, or peer-reviewed research were found describing the mechanism of action for Adipotide (FTPP). Without scientific evidence from clinical studies or laboratory research, the molecular and physiological mechanisms by which this compound may work cannot be accurately described.

Any claims about how Adipotide functions at the cellular or systemic level would be speculative without supporting research data. Healthcare providers and patients should be aware that the absence of published evidence means the safety, efficacy, and mechanism of action remain unestablished through rigorous scientific study.

This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider before considering any therapeutic intervention.

Clinical Applications

No clinical evidence currently available. Our search of medical databases found no published clinical trials or research papers evaluating adipotide (FTPP) in human patients.

Without peer-reviewed clinical data, it is not possible to provide evidence-based information about:

  • Approved medical uses or indications
  • Clinical effectiveness for any conditions
  • Safety profile in human patients
  • Appropriate dosing or administration protocols

Adipotide appears to be an experimental compound that has not progressed to documented human clinical testing. Any claims about clinical applications would lack scientific substantiation at this time.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for guidance on approved treatments for specific medical conditions.

Safety Profile

Evidence Status: No published clinical trials or peer-reviewed safety data were retrieved for Adipotide (FTPP) in humans.

Current Safety Information: Due to the absence of published clinical trial data, the complete safety profile of Adipotide (FTPP) in humans remains unknown. The following safety considerations are based on extremely limited available information:

Known Limitations:

  • No established human safety data from controlled clinical trials
  • No documented side effect profile from human studies
  • Unknown drug interactions
  • No established contraindications based on clinical evidence
  • Dosing safety parameters have not been established

Precautionary Considerations:
Given that Adipotide is designed as a targeted therapy that affects blood vessels in adipose tissue, theoretical concerns may include:

  • Potential cardiovascular effects (theoretical, not clinically demonstrated)
  • Unknown effects on wound healing or tissue repair
  • Undetermined impact on normal physiological processes

Populations of Concern:
Without clinical safety data, it is impossible to identify specific populations who should avoid this compound. Standard precautionary approaches would suggest particular caution in:

  • Pregnant or nursing women
  • Children and adolescents
  • Individuals with cardiovascular conditions
  • Those with bleeding disorders
  • Patients taking anticoagulant medications

Critical Safety Gap: The absence of published human clinical trial data represents a significant safety information gap. Any use of this compound outside of properly conducted clinical trials would carry unknown and potentially serious risks.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Consult with qualified healthcare providers regarding any experimental treatments or therapies.

Key Research Papers

Research Papers and Clinical Trials

No published research papers or registered clinical trials were found in major databases for Adipotide (FTPP).

This absence of peer-reviewed literature and clinical trial registrations indicates that Adipotide (FTPP) has not undergone formal scientific evaluation through the standard research and regulatory pathways. Without published studies, there is no available evidence regarding its safety profile, efficacy, optimal dosing, potential side effects, or clinical outcomes.

The lack of research data means that any claims about this compound's effects, mechanisms of action, or therapeutic potential cannot be verified through established scientific evidence. Healthcare providers and patients should be aware that treatments without published research backing lack the safety and efficacy validation that comes from peer-reviewed studies and controlled clinical trials.

This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before considering any treatment options.

Clinical Protocols

Protocols

No established clinical protocols are available for adipotide (FTPP). Based on the evidence search, no clinical trials or published studies were retrieved that describe human dosing or administration protocols for this compound.

Without published clinical data, no standard dosing regimens, administration routes, treatment durations, or safety monitoring protocols can be reported from the medical literature.

Any dosing information that might exist would be limited to preclinical research or unpublished studies, which cannot provide reliable guidance for clinical use.

Important Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. The absence of established protocols means adipotide should not be used outside of properly designed clinical research settings with appropriate regulatory oversight and medical supervision. Always consult with qualified healthcare professionals before considering any experimental treatments.

Outcomes & Evidence

Based on the evidence search, no published clinical studies or trials were retrieved for Adipotide (FTPP) that report measurable clinical outcomes.

Evidence Status: There is currently no accessible peer-reviewed literature documenting clinical outcomes for Adipotide (FTPP) in human studies. Without published clinical data, it is not possible to report on:

  • Biomarker changes
  • Symptom improvement
  • Safety profiles
  • Efficacy measures
  • Patient-reported outcomes

Strength of Evidence: The evidence base for clinical outcomes is absent from the accessible medical literature. Any claims about therapeutic effects, safety, or efficacy cannot be substantiated based on the current evidence search.

Disclaimer: This assessment is based solely on available published evidence and should not be considered medical advice. Consult healthcare providers for information about any experimental or investigational therapies.